Yang Dajun: Building high dikes, consolidating differentiated advantages, more than "surviving"

Benefiting from the reform of the drug approval system launched since 2015, the green channel of the capital market and the new policy of medical insurance payment, there is no doubt that

The reason for the uneven performance is determined by the comprehensive strength of the enterprise, and in the previous market of "pigs can fly", it is not easy to be screened by the outside world

Dr.

After the release of the expected results, Asun Pharmaceutical also disclosed that it would concentrate its resources more on the field of apoptosis drugs in the

Dr.

Adjust the focus and adhere to the determination of innovation-based

Yasheng Pharmaceutical invested 341 million yuan in R&D in the first half of 2022, which was basically the same as H1 in 2021, and maintained a slight gap of

Although in the cold winter environment of innovative drugs, it is fortunate that Yasheng Pharmaceutical has achieved commercialization, and the listing of "orebatinib" has brought nearly 100 million yuan of revenue to the company in the first half of the year, making it more targeted

As one of the strongest Biotechs in China, Yasheng Pharmaceutical has an independently constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug research and development in the apoptosis pathway, with a total of 9 class 1 small molecule new drugs that have entered the clinical development stage, and all of them are independently developed, with the best potential of the same kind or the best of

Product pipelines

For pharmaceutical companies, resources are always limited

Patent layout

The controversy over innovative drugs is essentially a dispute over

Open source and throttling, "two-pronged" to further build high dikes

Since its approval for listing in China in November last year, "Orebatinib" has received a number of authoritative clinical guidelines and has entered the Huimin Insurance Project in 10 provinces and 34 cities, greatly improving accessibility

Domestically, Asunit Pharma and Innovent Biotech have reached a potential US$245 million collaboration to jointly commercialize orepatinib in the Chinese market and explore the clinical development of other products for combined use; in terms of internationalization, it has joined hands with Tanner Pharma to launch the Designated Patient Drug Use Program (NPP), which is similar to Hainan's Boao model

Compared with the vast majority of 18A innovative drug companies, Asunit Pharmaceutical can be said to have a high enough "safety cushion", but the company seems to be more than a small goal

If the successful commercialization of "orepatinib" is an important measure of Yasheng Pharmaceutical in "open source", then its efforts in innovative research and development for more than ten years are not only "storing water" in its future product pool, but also expected to achieve "throttling" effect

The above recognition from the global authoritative regulatory authorities will not only save the company up to tens of millions of dollars in registration fees, but also is expected to shorten the time

Yasheng Pharmaceutical also has monetary funds of about 1.

Apoptosis drugs are a relatively niche and risky area of drug development, coupled with many MNC-related clinical projects or or no disease, the only successful marketing of drugs is bcl-2 inhibitor Venetoclax
.
As mentioned above, Aeson Pharmaceutical has laid out a number of projects in this field, and the progress of clinical research has frequently appeared in international academic conferences
.
For example, the 2022 ASCO Annual Meeting disclosed that the BCL-2 inhibitor APG-2575 produced 67.
4% of ORR excellent performance
in Patients with R/R CLL/SLL in China.

APG-2575 clinical data disclosed on ASCO 2022

Yang Dajun said that "scientific foundation, data-oriented" is one of the corporate cultures of Yasheng Pharmaceutical, the company follows a scientific attitude from top to bottom, relies on data to make decisions, and regards research and development capabilities as the driving force for
development.

More than "live"

Yang Dajun, who has been working in the field of innovative drugs for more than 30 years, is not the first time that he has experienced a capital winter, and the "capital winter" encountered in the first few years of his entrepreneurship is more severe and challenging
than the present.
After a long period of hard work, "two aspects" seems to have become his mantra
when it comes to articulating his views on something.

"Two aspects", just as drugs need to balance "safety" and "effectiveness", and they are also similar to the need to balance "risk" and "benefit" when making
investments.
In Yang Dajun's view, the same is true for doing business, and you can't think
one-way.

Now that the industry is in a new round of adjustment, the enterprises that survive the big wave will usher in better development
.
Although it is once again facing a cold winter in the industry, the most difficult time for Yasheng Pharmaceutical has passed
.
Yang Dajun said that the company's transition from research and development to commercialization is an important milestone, and the future management and evaluation indicators are completely different
.
Although Yasheng Pharmaceutical has achieved good results in the first year of commercialization, it is even more necessary to face up to the various opportunities
brought by challenges to enhance the ability of the team.

Yang Dajun, a scientist by training, led and witnessed the whole process of registration and commercialization of the company's first product, and also realized the transformation
of the role of an entrepreneur.
He said bluntly, whether he was a scientist or an entrepreneur
.
No matter what the outside world evaluates, he often thinks, what is his responsibility for the enterprise, the society, and the times?

"Responsible" is the three words
that Yang Dajun repeatedly mentioned after "two aspects".

He admits that innovation itself is not fashionable, innovation means failure, and the hardest thing about innovative drug development is persistence
.
Perhaps the only way to survive the winter is to stick to doing the right and professional things
.
Because the capital winter is both an opportunity and a challenge for innovation and development, the most important thing is to have confidence, and confidence comes from the times
.
The trend of the times in which we live is that Chinese biomedicine is going global and contributing to patients around the
world.